Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Castellanos-Montealegre, M; Rivera-Theruel, F; Garcia-Coll, V; Rioja-Collado, N; Gil-Herrero, L; Lopez-Tarruella, S; Sanz, MM; Gonzalez, SC; Aramburo, AF; Ruiz-Casado, A; Laundos, R; Casla-Barrio, S.

Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer

Current Oncology. 2023; 30(6): 5395-5408 Nº de citas: 1 [doi:10.3390/curroncol30060409]

Arranz-Herrero, J; Presa, J; Rius-Rocabert, S; Utrero-Rico, A; Arranz-Arija, JA; Lalueza, A; Escribese, MM; Ochando, J; Soriano, V; Nistal-Villan, E.

Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2023; 131: 173-179 Nº de citas: 29 [doi:10.1016/j.ijid.2023.04.003]

Jimenez-Fonseca, P; Sastre, J; Garcia-Alfonso, P; Gomez-Espana, MA; Salud, A; Gil, S; Rivera, F; Reina, JJ; Quintero, G; Valladares-Ayerbes, M; Safont, MJ; La Casta, A; Robles-Diaz, L; Garcia-Paredes, B; Lopez, RL; Guillot, M; Gallego, J; Alonso-Orduna, V; Diaz-Rubio, E; Aranda, E.

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNu-1 and Phase II VISNu-2 Randomized Trials

Clinical Colorectal Cancer. 2023; 22(2): 222-230 Nº de citas: 3 [doi:10.1016/j.clcc.2023.02.004]

Alvarez, RA; Manzano, A; Pujol, CA; Raventos, VA; Correa, R; Jurado, JC; Fernandez, JA; del Muro, XG; Gonzalez, JA; Hindi, N; Lominchar, PL; Martinez-Trufero, J; Mendez, R; Munoz, M; Casares, CM; Castellanos, FO; Fernandez, RO; Gonzalez, MP; Redondo, A; Morales, CV; Asencio, JM.

Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

Cancers. 2023; 15(12): Nº de citas: 10 [doi:10.3390/cancers15123194]

Verso, M; Munoz, A; Agnelli, G.

Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

SEMINARS IN ONCOLOGY. 2023; 50(3-5): 67-70 Nº de citas: 3 [doi:10.1053/j.seminoncol.2023.05.002]

Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM.

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.

JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(16): 2911-2925 Nº de citas: 46 [doi:10.1200/JCO.22.00255]

Vedovati, MC; Giustozzi, M; Munoz, A; Bertoletti, L; Cohen, AT; Klok, FA; Connors, JM; Bauersachs, R; Brenner, B; Campanini, M; Becattini, C; Agnelli, G.

Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

European Journal of Internal Medicine. 2023; 112: 29-36 Nº de citas: 38 [doi:10.1016/j.ejim.2023.02.003]

Ruiz-Briones, P; Escudero-Vilaplana, V; Collado-Borrell, R; Vicente-Valor, J; Alvarez, R; Villanueva-Bueno, C; Narrillos-Moraza, A; Herranz, A; Sanjurjo, M.

Possible heart failure caused by osimertinib in a lung cancer patient

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2023; 29(4): 1015-1020 Nº de citas: 4 [doi:10.1177/10781552221143787]

Bueno-Muino, C; Echavarria, I; Lopez-Tarruella, S; Roche-Molina, M; del Monte-Millan, M; Massarrah, T; Jerez, Y; de la Pena, FA; Garcia-Saenz, JA; Moreno, F; Rodriguez-Lescure, A; Malon-Gimenez, D; Garcia, AIB; Marin-Aguilera, M; Galvan, P; Braso-Maristany, F; Waks, AG; Tolaney, SM; Mittendorf, EA; Vivancos, A; Villagrasa, P; Parker, JS; Perou, CM; Pare, L; Villacampa, G; Prat, A; Martin, M.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

JAMA Oncology. 2023; 9(6): 841-846 Nº de citas: 27 [doi:10.1001/jamaoncol.2023.0187]

Verso, M; Munoz, A; Connors, JM.

Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

Internal and Emergency Medicine. 2023; 18(6): 1619-1634 Nº de citas: 3 [doi:10.1007/s11739-023-03306-8]

Zatarain-Nicolas, E; Martin, P; Rodas, IM; Virizuela, J; Garcia, AM; Mitroi, C; Sales, JC; Barrios, V; Sanchez-Cabo, F; Ibanez, B; Carpeno, JD; Fernandez, TL.

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Clinical & Translational Oncology. 2023; 25(11): 3073-3085 Nº de citas: 4 [doi:10.1007/s12094-023-03217-2]

Capdevila, J; Hernando, J; Teule, A; Lopez, C; Garcia-Carbonero, R; Benavent, M; Custodio, A; Garcia-Alvarez, A; Cubillo, A; Alonso, V; Carmona-Bayonas, A; Alonso-Gordoa, T; Crespo, G; Jimenez-Fonseca, P; Blanco, M; Viudez, A; La Casta, A; Sevilla, I; Segura, A; Llanos, M; Landolfi, S; Nuciforo, P; Manzano, JL.

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Nature Communications. 2023; 14(1): Nº de citas: 47 [doi:10.1038/s41467-023-38611-5]

Sanchez-Canovas, M; Jimenez-Fonseca, P; Garay, DF; Solis, MC; Elia, DC; Salvans, EC; Vacas, ID; Sanchez, DG; Montes, AF; Gimenez, RM; de Tejada, MBG; Arrula, VA; Lopez, SS; Candelera, RO; Cendra, CS; de la Pena, MJ; Munoz, DM; Sarmiento, MO; de Castro, EM; Escobar, IG; Vidal, AB; Moran, LO; Martin, AJM; Bayona, RS; Ortiz, MJM; de la Pena, FA; Vicente, V; Carmona-Bayonas, A.

Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

PLoS One. 2023; 18(5): Nº de citas: 3 [doi:10.1371/journal.pone.0266305]

Garcia-Saenz, JA; Blancas, I; Echavarria, I; Hinojo, C; Margeli, M; Moreno, F; Pernas, S; Cajal, TRY; Ribelles, N; Bellet, M.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)

Clinical & Translational Oncology. 2023; 25(9): 2665-2678 Nº de citas: 21 [doi:10.1007/s12094-023-03203-8]

Gravalos, C; Pereira, F; Vera, R; Arjona-Sanchez, A; Losa, F; Ramos, I; Garcia-Alfonso, P; Gonzalez-Bayon, L; Cascales-Campos, PA; Aranda, E.

Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

Clinical & Translational Oncology. 2023; 25(12): 3378-3394 Nº de citas: 2 [doi:10.1007/s12094-023-03204-7]

Montes, AF; Alonso, V; Aranda, E; Elez, E; Alfonso, PG; Gravalos, C; Maurel, J; Vera, R; Vidal, R; Aparicio, J.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

Clinical & Translational Oncology. 2023; 25(9): 2718-2731 Nº de citas: 10 [doi:10.1007/s12094-023-03199-1]

Serrano, C; Alvarez, R; Carrasco, JA; Marquina, G; Martinez-Garcia, J; Martinez-Marin, V; Sala, MA; Sebio, A; Sevilla, I; Martin-Broto, J.

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Clinical & Translational Oncology. 2023; 25(9): 2707-2717 Nº de citas: 12 [doi:10.1007/s12094-023-03177-7]

Slamon, DJ; Fasching, PA; Hurvitz, S; Chia, S; Crown, J; Martin, M; Barrios, CH; Bardia, A; Im, SA; Yardley, DA; Untch, M; Huang, CS; Stroyakovskiy, D; Xu, BH; Moroose, RL; Loi, S; Visco, F; Bee-Munteanu, V; Afenjar, K; Fresco, R; Taran, T; Chakravartty, A; Zarate, JP; Lteif, A; Hortobagyi, GN.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 85 [doi:10.1177/17588359231178125]